Current Enrolling Studies

 Heart Failure Studies

  1. ZOLL HF OPT: (Heart Failure Optimization Study):  A prospective observational study to observe the rate of recovery of ventricular function (EF > 35%) between 90 and 180 days in newly diagnosed HF patients.
    INVESTIGATOR:  Dr. Judson Colley
    SPONSOR:  ZOLL Medical Corporation
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT03016754?term=zoll+HF+OPT&rank=1

    CONTACT INFORMATION:  Linda Stucky, BSN, CCRC  601-982-7850 ext. 540  Email: lstucky@jacksonheart.com
  2. VIVID: The use of an Educational Video to Improve Patient Decision Making and Racial Disparities in the Implantation of Implanted Cardioverter Defibrillators (ICD).
    INVESTIGATOR: Dr. Judson Colley
    SPONSOR: PCORI/DCRI
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT02819973?term=Pro00071154&rank=1
    CONTACT INFORMATION
    Linda Stucky, BSN, CCRC 601-982-7850, ext. 540 Email: lstucky@jacksonheart.com
  3. EMPEROR:  EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure
    EMPEROR-Preserved
    INVESTIGATORS:  Dr. Clay Hays, Jr., Dr. Douglas Harkins, Dr. James G. Bennett
    SPONSOR:  Boehringer Ingelheim
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT03057977?term=EMPEROR&rank=1
    CONTACT INFORMATION:
    Jamie Neal, RN  601-982-7850, ext 541  Email:  jneal@jacksonheart.com
  4. PARADISE Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI)
    INVESTIGATORS:  Dr. Richard Guynes, Dr. Clay Hays, Jr.
    SPONSOR:  Novartis
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT02924727?term=PARADISE&rank=6

    CONTACT INFORMATION:
    Rose Cheatham, CRC 601-982-7850, ext. 267 Email: rcheatham@jacksonheart.com
  5. HOME Predict-HFHome Outpatient Monitoring and Engagement to Predict HF
    Exacerbation
    INVESTIGATOR: Dr. Clay Hays
    SPONSOR: American College of Cardiology
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT03479424?term=Home+Predict+HF&rank=1
    CONTACT INFORMATION:
    Sandy Puckett, RN 601-982-7850, ext. 543 Email: swpuckett@jacksonheart.com

Pacemaker/Defibrillator Studies

  1. BRADY MRI Post Approval Study
    INVESTIGATOR:  Dr. Judson Colley
    SPONSOR:  St. Jude/Abbott
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT03170583?term=Brady+MRI&rank=1
    CONTACT INFORMATION
    Jamie Neal, RN  601-982-7850 ext. 541   Email: jneal@jacksonheart.com

Atrial Fibrillation Studies

  1. ENSITE Precision Observational Study
    INVESTIGATOR: Dr. Judson Colley
    SPONSOR:
    St. Jude/Abbott
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT03260244?term=EnSite+Precision+Observational+study&rank=1
    CONTACT INFORMATION
    Jamie Neal, RN  601-982-7850 ext. 541   Email: jneal@jacksonheart.com
  2. DIAMOND-AF II STUDY – A Prospective Clinical Evaluation of the DiamondTemp™ System for the Treatment of
    Persistent Atrial Fibrillation
    INVESTIGATOR: Dr. Judson Colley
    SPONSOR: Trireme Medical, LLC
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT03643224?term=DiamondTemp&rank=4
    CONTACT INFORMATION:
    Rose Cheatham, CRC 601-982-7850, ext. 267 Email: rcheatham@jacksonheart.com
  3. PERSIST-END Trial – Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE)
    Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
    INVESTIGATOR: Dr. Judson Colley
    SPONSOR: Abbott
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT03650556?term=persist+end&rank=1
    CONTACT INFORMATION:
    Jamie Neal, RN 982-7850, ext. 541 Email: jneal@jacksonheart.com

VALVULAR DISEASE

  1. ENVISAGE-TAVI:  EDOXABAN VERSUS STANDARD OF CARE AND THEIR EFFECTS ON CLINICAL OUTCOMES IN PATIENTS HAVING UNDERGONE TRANSCATHETER AORTIC VALVE IMPLANTATION – IN ATRIAL FIBRILLATION
    INVESTIGATOR:  Dr. William Crowder
    SPONSOR:  Daiichi Sankyo
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT02943785?term=envisage+tavi&rank=1
    CONTACT INFORMATION
    Linda Stucky, BSN, CCRC 601-982-7850, ext. 540 Email: lstucky@jacksonheart.com

CARDIOVASCULAR STENTING STUDIES

  1. XIENCE 90 Study
    INVESTIGATOR: Dr. Brett Bennett, Dr. Russell Young
    SPONSOR: Abbott Cardiovascular
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT03218787?term=XIENCE+90&rank=1
    CONTACT INFORMATION:
    Sandy Puckett, RN 601-982-7850, ext. 543 Email: swpuckett@jacksonheart.com
  2. Chocolate Touch Study – Paclitaxel Coated PTA Balloon Catheter, in Above the Knee Lesions
    INVESTIGATOR: Dr. William Crowder, Dr. G. Bennett
    SPONSOR: Trireme Medical, LLC
    For eligibility criteria and more information:
    https://clinicaltrials.gov/ct2/show/NCT02924857?term=Chocolate+Touch&rank=1
    CONTACT INFORMATION:
    Sandy Puckett, RN 601-982-7850, ext. 543 Email: swpuckett@jacksonheart.com

If you would like to be considered for these studies or for future studies, sign up on our Patient Registry.

Menu